Lagatar24 Desk
New Delhi, Dec 11: To allow recipients of the vaccination to receive a certificate of vaccination, Bharat Biotech has asked the central government to put their intranasal COVID-19 vaccine, iNCOVACC, in the CoWIN portal.
According to company sources, Bharat Biotech is currently in talks with foreign ‘possible partners’ who have contacted the business about producing and distributing the intranasal vaccine internationally.
“Since iNCOVACC has been approved for restricted use under emergency situations and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunisation program against covid,” the sources told PTI.
The CoWin portal currently lists Covaxin by Bharat Biotech, Covishield and Covovax by Serum Institute, Russian Sputink V, and Corbevax by Biological E Ltd.
On September 6, the vaccine producer stated that the world’s first intranasal COVID-19 vaccine, iNCOVACC (BBV154), has been given the nod by India’s Drugs Controller General under the category of Restricted Use in Emergency Situations for anyone aged 18 and over.
Once it receives the necessary approvals from the other countries, the city-based vaccine manufacturer also intends to ship iNCOVACC there, according to sources.
The Central Drugs Standard Control Organization (CDSCO) in India has also approved iNCOVACC (BBV154) for heterologous booster dosages under Restricted Use in Emergency Situations for those aged 18 and over.
